Anzeige
+++Wall Street steigt ein: Trump, CFTC, Cantor Fitzgerald – und mittendrin dieser 22-Mio.-Small-Cap an der Crypto.com-Börse Trump, CFTC, Cantor Fitzgerald – und mittendrin dieser 22-Mio.-Small-Cap an der Crypto.com-Börse+++
PortfolioPlus
Portfolio-Tracker – Kurse, Renditeanalyse und Dividendenplaner an einem Ort.
Anzeige
Original-Research

Cantourage Group SE (von NuWays AG): BUY 14.08.2026, 09:00 Uhr von EQS Research Jetzt kommentieren: 0

Werte zum Artikel
Name Aktuell Diff. Börse
Cantourage Group 5,89 EUR +0,51 % Lang & Schwarz

Original-Research: Cantourage Group SE - from NuWays AG

14.08.2026 / 09:00 CET/CEST
Dissemination of a Research, transmitted by EQS News - a service of EQS Group.
The issuer is solely responsible for the content of this research. The result of this research does not constitute investment advice or an invitation to conclude certain stock exchange transactions.


Classification of NuWays AG to Cantourage Group SE

Company Name: Cantourage Group SE
ISIN: DE000A3DSV01
 
Reason for the research: Update
Recommendation: BUY
Target price: EUR 10.5
Target price on sight of: 12 months
Last rating change:
Analyst: Christian Sandherr

H1 out: Margins over sales is increasingly paying off; chg.

Topic: Cantourage released Q2'26 figures showing a further step-up in earnings quality. Sales declined yoy on a deliberate exit from low-margin German volumes, while EBITDA grew 45% yoy.

Q2 sales came in at € 21.8m, down 21.9% yoy but up 5.8% qoq (Q1'26: € 20.6m), marking the second consecutive quarter of sequential growth. Importantly, the yoy optic reflects the last hard comparable of the cycle: Q2'25 (€ 27.9m) was the peak quarter of the German volume boom, before the price war in the standard flower segment set in. With Q3'25 and Q4'25 at c. € 19.9m and € 18.6m respectively, group sales should return to yoy growth from Q3'26e onwards (eNuW).

Geographic rebalancing. Germany contributed € 10.1m (-56% yoy), or 46% of group sales, versus 84% in Q2'25, as management has largely discontinued low-margin strains (oversupply + significant market price reductions). Importantly, Q2 should mark the floor, with management pointing towards sequential growth as premium supply expands. Mind you, the ramp is supply- rather than demand-constrained: premium volumes require biomass that takes time to scale, while new form factors (edibles, extracts) await import permits currently taking 7-8 weeks instead of the statutory 10-14 working days, pushing first batches into Q4.

The UK grew 146% yoy to € 9.6m (ramp up of its clinic) and is now effectively at parity with the home market, while Poland tripled to € 2.1m. For the first time, the majority of group revenue was generated outside Germany, an important de-risking event in the equity story: the German price cycle and the still unresolved domestic regulatory debate are no longer the dominant swing factor for group earnings. Management has flagged France, Spain and Italy as potential next entries over the medium term.

gramz. is an early validation of the own-brand strategy. The house brand launched in Q2 generated some € 0.5m sales in its first partial quarter with initial batches selling out. While immaterial in absolute terms, it underpins that Cantourage is able to successfully distribute own rather than only third-party products.

All eyes on profitability. The gross margin expanded by 7.9pp yoy to 36.4%, the clearest evidence that the strategy shift (focus on premium flowers) is working out well. Q2 EBITDA rose 45% yoy to € 2.9m, a 13.1% margin (+6.1pp yoy, +2.5pp qoq). With this, H1'26 EBITDA thus stands at € 5.1m (12.0% margin), already well ahead of our old 9.8% FY26e.

Two short-term catalysts ahead. Management is expected to release a FY26 guidance which should be carried by a high FY EBITDA margin, in our view. Mind you, FY25p margin stood at 6.1%. Cantourage should also release the final consolidated FY25 report early September, decreasing risk discounts that are likely baked into the current share price.

At 6.2x FY26e and 4.8x FY27e EV/EBITDA, the valuation of Cantourage remains attractive. For reference, Organigram acquired Sanity Group at c. 4.2x EV/sales for a wholesale-only, barely profitable asset, against c. 0.7x for Cantourage with a double-digit and rising EBITDA margin. We confirm our BUY rating with a slightly raised € 10.50 PT (old: € 10.00) based on DCF.

You can download the research here: cantourage-group-se-2026-08-14-previewreview-en-0058d
For additional information visit our website: https://www.nuways-ag.com/research

Contact for questions:
NuWays AG - Equity Research
Web: www.nuways-ag.com
Email: research@nuways-ag.com
LinkedIn: https://www.linkedin.com/company/nuwaysag
Adresse: Mittelweg 16-17, 20148 Hamburg, Germany
++++++++++
Diese Meldung ist keine Anlageberatung oder Aufforderung zum Abschluss bestimmter Börsengeschäfte.
Offenlegung möglicher Interessenkonflikte nach § 85 WpHG beim oben analysierten Unternehmen befindet sich in der vollständigen Analyse.
++++++++++


The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
View original content: EQS News


2382954  14.08.2026 CET/CEST

Kommentare (0) ... diskutiere mit.
Werbung

Ihre Lieblingsaktie geschenkt

BörsenNEWS.de und Smartbroker+ starten gemeinsam eine exklusive Bonus-Aktion. Eröffnen Sie bis 31.08.2026 ein Depot bei Smartbroker+ und erhalten als Willkommensgeschenk einen Anteil ausgewählter Aktien im Wert von 50 Euro!.

k.A. k.A. k.A. k.A.
k.A. k.A. k.A. k.A.
k.A. k.A. k.A. k.A.
Schreib den ersten Kommentar!

Dis­clai­mer: Die hier an­ge­bo­te­nen Bei­trä­ge die­nen aus­schließ­lich der In­for­ma­t­ion und stel­len kei­ne Kauf- bzw. Ver­kaufs­em­pfeh­lung­en dar. Sie sind we­der ex­pli­zit noch im­pli­zit als Zu­sich­er­ung ei­ner be­stim­mt­en Kurs­ent­wick­lung der ge­nan­nt­en Fi­nanz­in­stru­men­te oder als Handl­ungs­auf­for­der­ung zu ver­steh­en. Der Er­werb von Wert­pa­pier­en birgt Ri­si­ken, die zum To­tal­ver­lust des ein­ge­setz­ten Ka­pi­tals füh­ren kön­nen. Die In­for­ma­tion­en er­setz­en kei­ne, auf die in­di­vi­du­el­len Be­dür­fnis­se aus­ge­rich­te­te, fach­kun­di­ge An­la­ge­be­ra­tung. Ei­ne Haf­tung oder Ga­ran­tie für die Ak­tu­ali­tät, Rich­tig­keit, An­ge­mes­sen­heit und Vol­lständ­ig­keit der zur Ver­fü­gung ge­stel­lt­en In­for­ma­tion­en so­wie für Ver­mö­gens­schä­den wird we­der aus­drück­lich noch stil­lschwei­gend über­nom­men. Die Mar­kets In­side Me­dia GmbH hat auf die ver­öf­fent­lich­ten In­hal­te kei­ner­lei Ein­fluss und vor Ver­öf­fent­lich­ung der Bei­trä­ge kei­ne Ken­nt­nis über In­halt und Ge­gen­stand die­ser. Die Ver­öf­fent­lich­ung der na­ment­lich ge­kenn­zeich­net­en Bei­trä­ge er­folgt ei­gen­ver­ant­wort­lich durch Au­tor­en wie z.B. Gast­kom­men­ta­tor­en, Nach­richt­en­ag­en­tur­en, Un­ter­neh­men. In­fol­ge­des­sen kön­nen die In­hal­te der Bei­trä­ge auch nicht von An­la­ge­in­te­res­sen der Mar­kets In­side Me­dia GmbH und/oder sei­nen Mit­ar­bei­tern oder Or­ga­nen be­stim­mt sein. Die Gast­kom­men­ta­tor­en, Nach­rich­ten­ag­en­tur­en, Un­ter­neh­men ge­hör­en nicht der Re­dak­tion der Mar­kets In­side Me­dia GmbH an. Ihre Mei­nung­en spie­geln nicht not­wen­di­ger­wei­se die Mei­nung­en und Auf­fas­sung­en der Mar­kets In­side Me­dia GmbH und de­ren Mit­ar­bei­ter wie­der. Aus­führ­lich­er Dis­clai­mer